Spatial transcriptomics and immunophenotyping uncover chronic inflammation-induced immune adaptations favoring dysplasia development in patients at risk of colitis-associated cancer - Scorecard - MDSpire
Advertisement
Spatial transcriptomics and immunophenotyping uncover chronic inflammation-induced immune adaptations favoring dysplasia development in patients at risk of colitis-associated cancer
Clinical Scorecard: Spatial Transcriptomics and Immune Profiling Reveal Immune Adaptations Induced by Chronic Inflammation That Promote Dysplasia in Colitis-Associated Cancer Risk Patients
At a Glance
Category
Detail
Condition
Colitis-associated cancer (CAC) in inflammatory bowel disease (IBD)
Key Mechanisms
Chronic inflammation induces endogenous anti-inflammatory mechanisms including increased IL-10 production and decreased CD8+ intraepithelial T cells, reducing immunosurveillance and promoting dysplasia
Target Population
Patients with inflammatory bowel disease at risk for developing colitis-associated cancer
Care Setting
Gastroenterology clinics with access to colonoscopic surveillance and histopathological evaluation
Key Highlights
Histologically uninflamed colon mucosa in CAC patients shows upregulated metabolism and stress response pathways indicating ongoing epithelial stress.
Increased IL-10 expression by lamina propria IgA+ plasma cells and CD163+ macrophages represents endogenous anti-inflammatory adaptations.
Reduced CD8+ intraepithelial lymphocyte density and granzyme B levels correlate with decreased immunosurveillance and higher CAC susceptibility.
Guideline-Based Recommendations
Diagnosis
Use histological assessment to identify uninflamed, non-dysplastic mucosa adjacent to lesions in IBD patients.
Employ spatial transcriptomics and immunophenotyping to detect immune adaptations in mucosa at risk for CAC.
Management
Maintain regular colonoscopic surveillance in IBD patients, especially those with long-standing disease or primary sclerosing cholangitis.
Consider monitoring immune cell profiles, including CD8+ intraepithelial lymphocytes, to stratify CAC risk.
Monitoring & Follow-up
Perform yearly colonoscopic biopsies of normal-appearing mucosa for histological and immunological evaluation.
Track changes in anti-inflammatory cytokine expression and CD8+ IEL density over time.
Risks
Chronic inflammation-induced immunosuppressive microenvironment may undermine immunosurveillance, increasing dysplasia and CAC risk.
Reduced CD8+ IELs and increased IL-10 may limit inflammation but favor tumorigenesis.
Patient & Prescribing Data
IBD patients undergoing surveillance for dysplasia and CAC risk
Limited biologic exposure noted; immune adaptations occur despite remission, suggesting need for therapies targeting immunosuppressive pathways to improve immunosurveillance.
Clinical Best Practices
Integrate spatial transcriptomics and multiplex immunophenotyping for early detection of immune alterations in IBD mucosa.
Focus on both pro-inflammatory and anti-inflammatory immune pathways to understand CAC risk.
Use CD8+ intraepithelial lymphocyte density as a potential biomarker for CAC susceptibility in IBD patients.
by Sofía Frigerio, Hina N Khan, Mojtaba Amini, Bregje Mol, Andra Neefjes-Borst, Manon E Wildenberg, Cyriel Y Ponsioen, Geert R D’Haens, Yvonne Vercoulen, Joep Grootjans
